论文部分内容阅读
目的探讨NSE、CYFRA21-1、CA125三种肿瘤标志物联合检测在肺癌诊断中的价值。方法采用电化学发光法(ECLIA)检测56例肺癌,30例肺良性疾病和30例健康体检者血中神经元特异性烯醇化酶(NSE)、细胞角蛋白21-1(CYFRA21-1)、糖类抗原125(CA125)的含量。结果肺癌组血中NSE、CYFRA21-1、CA125的含量明显高于肺良性病变组和正常对照组,差异具有统计学意义(P<0.05)。NSE、CYFRA21-1、CA125对肺癌的敏感性分别为80.3%、78.6%、91.1%;三项联检敏感性可达95.8%,准确性可达85.3%。结论联合检测可明显提高肺癌的敏感性和准确性。为早期诊断早治疗提供有力的证据。
Objective To investigate the value of combined detection of NSE, CYFRA21-1 and CA125 tumor markers in the diagnosis of lung cancer. Methods The levels of neuron-specific enolase (NSE), cytokeratin 21-1 (CYFRA21-1), interleukin-21 Carbohydrate antigen 125 (CA125) content. Results The levels of NSE, CYFRA21-1 and CA125 in lung cancer group were significantly higher than those in benign lung disease group and normal control group (P <0.05). The sensitivities of NSE, CYFRA21-1 and CA125 to lung cancer were 80.3%, 78.6% and 91.1% respectively. The sensitivity of three combined tests was 95.8% and the accuracy was 85.3%. Conclusion Combined detection can significantly improve the sensitivity and accuracy of lung cancer. Provide early evidence for early diagnosis and treatment.